Prof. Bhumsuk Keam

Seoul National University Hospital, Korea

Email: bhumsuk@snu.ac.kr

Qualifications

2007 Ph.D., Seoul National University College of Medicine

2004 M.D., Seoul National University College of Medicine

Publications (selected)

1. Go H, Kim DW, Kim D, Keam B, Kim TM, Lee SH, Heo DS, Bang YJ, Chung DH. Clinicopathologic Analysis of ROS1-Rearranged Non-Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm. J Thorac Oncol. 2013 Nov;8(11):1445-50.
2. Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol. 2013 Aug 6. [Epub]
3. Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol. 2013 Aug;8(8):1069-74.
4. Lim Y, Keam B, Koh Y, Kim TM, Lee SH, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS, Kim KH. Clinical Outcomes of Radiation-based Locoregional Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients Not Responding to Induction Chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2013 Jul;116(1):55-60
5. Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol. 2013 Aug;24(8):2080-7.
6. Keam B, Im SA, Lim Y, Han SW, Moon HG, Oh DY, Cho N, Lee SH, Han W, Moon WK, Kim DW, Kim TY, Park IA, Noh DY. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer. Ann Surg Oncol. 2013 Jul;20(7):2242-9
7. Lee KH, Keam B, Im SA, Kim TY, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data. J Breast Cancer. 2012 Dec;15(4):427-33.
8. Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS. Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2013 Jan 22. [Epub ahead of print]
9. Koo TR, Wu HG, Hah JH, Sung MW, Kim KH, Keam B, Kim TM, Lee SH, Kim DW, Heo DS, Park CI. Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer. Cancer Res Treat. 2012;44(4):227-34.
10. Kim EK, Ahn YO, Kim S, Kim TM, Keam B, Heo DS. Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers. Cytotherapy. 2013;15(2):231-241
11. Park JH, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, Chung DH, Kim YT, Kim YW, Heo DS. Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib. Clin Lung Cancer. 2013 Jan 9. [Epub ahead of print]
12. Keam B, Yun YH, Heo DS, Park BW, Cho CH, Kim S, Lee DH, Lee SN, Lee ES, Kang JH, Kim SY, Lee JL, Lee CG, Lim YK, Kim SY, Choi JS, Jeong HS, Chun M. The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. Support Care Cancer. 2012 Dec 22, [Epub ahead of print]
13. Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH, Kim DW, Lee DS, Kim CW, Chung JK, Kim IH, Heo DS. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2012 Dec 4.. [Epub ahead of print]
14. Lee HJ, Kim DY, Keam B, Lee JH, Han SW, Oh DY, Yoon JH, Kim TY, Kim YJ, Lee KW, Kim JW, Jeong SH, Lee JS, Kim JH, Im SA. Ÿ Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy. Breast Cancer. 2012 Oct 17. [Epub ahead of print]
15. Moon HG, Im SA, Han W, Oh DY, Han SW, Keam B, Park IA, Chang JM, Moon WK, Cho N, Noh DY. Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy : Distinct patterns of response according to ER expression. Breast Cancer Res Treat. 2012 Aug;134(3):1133-40.
16. Lee JK, Keam B, An AR, Kim TM, Lee SH, Kim DW, Heo DS. Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. Support Care Cancer. 2012 [Epub ahead of print]
17. Jeon YK, Go H, Nam SJ, Keam B, Kim TM, Jung KC, Kang HJ, Lee DS, Huh JR, Park SH. Expression of the promyelocytic leukemia zinc-finger in T-lymphoblastic lymphoma and leukemia has strong implications for their cellular origin and greater association with initial bone marrow involvement. Mod Pathol. 2012 [Epub ahead of print]
18. Park JH, Lee SH, Keam B, Kim TM, Kim DW, Yang SC, Kim YW, Heo DS. EGFR mutations as a predictive marker of cytotoxic chemotherapy.Lung Cancer. 2012 [Epub ahead of print]
19. Kim JW, Im SA, Kim M, Cha Y, Lee KH, Keam B, Kim MA, Han SW, Oh DY, Kim TY, Kim WH, Bang YJ. The Prognostic Significance of HER2 Positivity for Advanced Gastric Cancer Patients Undergoing First-line Modified FOLFOX-6 Regimen. Anticancer Res. 2012 ;32(4):1547-1553.
20. Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy. Breast Cancer. 2013 Apr;20(2):167-73.
21. Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer. 2011;11(1):452.
22. Keam B, Hwang JY, Go MJ, Heo JY, Park MS, Lee JY, Kim NH, Park M, Oh JH, Kim DH, Jeong JY, Lee JY, Han BG, Lee J. Genome-wide Association Study Identified TIMP2 Genetic Variant with Susceptibility to Osteoarthritis. Genomics & Informatics 2011;9(3): 121-126
23. Lee J, Keam B, Jang EJ, Park MS, Lee JY, Kim DB, Lee CH, Kim T, Oh B, Park HJ, Kwack KB, Chu C, Kim HL. Development of a Predictive Model for Type 2 Diabetes Mellitus Using Genetic and Clinical Data. Public Health Res Perspect 2011 2(2),75-82
24. Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Noh DY, Heo DS, Park IA, Bang YJ, Ha SW. Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol. 2011 Sep 22. [Epub ahead of print]
25. Keam B, Im SA, Park S, Nam BH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. J Cancer Res Clin Oncol. 2011: 137(9);1301-8
26. Keam B, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Canc Netw. 2011;9(5):465-77
27. Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011 Mar 2;13(2):R22. [Epub ahead of print]
28. Cho SC, Park MC, Keam B, Choi JM, Cho Y, Hyun S, Park SC, Lee J. DDS, 4,4'-diaminodiphenylsulfone, extends organismic lifespan. Proc Natl Acad Sci U S A. 2010 Oct 25. [Epub ahead of print]
29. Choi SJ, Keam B, Park SH, Park HY. Appropriate waist circumference cut-offs to predict diabetes in the Korean population - the Korean Genome and Epidemiology Study-. Circ J. 2010;74(7):1357-63
30. Lee JH, Yoon JH, Lee CH, Myung SJ, Keam B, Kim BH, Chung GE, Kim W, Kim YJ, Jang JJ, Lee HS. Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virus-related chronic liver disease patients. J Viral Hepat. 2009 Jun;16(6):444-52.
31. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy, Breast Cancer Res Treat. 2009 Jul;116(1):153-60
32. Chae YK, Kang SK, Kim MS, Woo J, Lee J, Chang S, Kim DW, Kim M, Park S, Kim I, Keam B, Rhee J, Koo NH, Park G, Kim SH, Jang SE, Kweon IY, Sidransky D, Moon C. Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML). PLoS ONE. 2008;3(7):e2594.
33. Keam B, Im SA, Han SW, Ham HS, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Bang YJ. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer. 2008 May 27;8:148.